Patients with homologous-recombination-deficient advanced ovarian cancer alive at 5 years were twice as likely to be progression free with niraparib than placebo, although no long-term overall survival benefit was reported
Improvements in the understanding of molecular mechanisms, together with a greater focus on prevention, are key elements to countering gynaecological malignancies
The phase II part of the ROCSAN trial failed to meet its primary endpoint but there may be potential for benefit based on efficacy and safety data with the combination
New survival data from the MIRASOL trial support the use of this antibody-drug conjugate as a preferred standard of care for patients with high folate receptor alpha tumour expression
While updated results from the DUO-O trial appear promising, they are not conclusive due to the study design
A multitude of new agents under development could finally offer meaningful treatment options to a patient population with high unmet need
Two studies presented by the French network TMRG-GINECO provide new insights into the treatment and quality of life of women with this rare cancer
Sustained benefit of PARPi treatment may help to put the recent concerns on how and when to use these agents in women into context
Unfavourable overall survival data for PARP inhibitors in certain ovarian cancers prompts calls for caution in interpretation of the analyses and stimulates the search for surrogate measures of clinical benefit
Expert says widely applicable predictive testing is needed to improve prevention, diagnosis and treatment
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.